Vaccines, Viagra, and Vioxx: Medicines, markets, and money - When life-saving meets life-style

Drug Development Research

Volumn 64, Issue 2, 2005, Pages 90-98

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Anti depressants; Direct to consumer advertising; Erectile dysfunction; Female sexual dysfunction; Flu vaccine; Happy pills; Human growth hormone; Life style diseases; Life style drugs; Short people; Social anxiety disorder

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; BOTULINUM TOXIN A; CANNABIS; COCAINE; CONTRACEPTIVE AGENT; CYCLOOXYGENASE 2 INHIBITOR; FINASTERIDE; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; MINOXIDIL; NICOTINE; PAROXETINE; ROFECOXIB; ROSUVASTATIN; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL; VENLAFAXINE;

ADVERTIZING; AGING; ARTHRITIS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CONSUMER; DIABETIC NEPHROPATHY; DRUG ABUSE; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; EATING DISORDER; ERECTILE DYSFUNCTION; FEMALE; FEMALE SEXUAL DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HAIR LOSS; HAPPINESS; HEALTH CARE COST; HORMONAL CONTRACEPTION; HUMAN; HYPERLIPIDEMIA; INFECTION; INFLUENZA; INFLUENZA VACCINATION; IRRITABLE COLON; IRRITABLE MALE SYNDROME; LAW SUIT; LIFESTYLE; LUNG CANCER; MALE; MALE SEXUAL DYSFUNCTION; MENTAL DISEASE; OBESITY; PRESCRIPTION; REVIEW; SEXUAL DYSFUNCTION; SHORT STATURE; SOCIAL PHOBIA; TESTOSTERONE BLOOD LEVEL; URINE INCONTINENCE; VACCINATION; VIRUS INFECTION;

EID: 19944383818     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10429     Document Type: Review

References (54)

1. Alonso-Zaldivar R. 2004. Congressman's new job is top drug lobbyist. Los Angeles Times, 16 December.
2. Angell M. 2004. The truth about drug companies. How they deceive us and what to do about it. New York: Random House.
3. Anonymous. 2004. Comment and analysis. Merck's fall from grace: after Vioxx how can the drugs giant regain its reputation? Financial Times, 18 November.
4. Basson R, Althof S, Davis S, Fugi-Meyer K, Goldstein I, Leiblum S, Meston C, Rosen R, Wagner G. 2004. Summary of the recommendations on sexual dysfunctions in women. J Sex Med 1:24-34.
5. Conrad P, Potter D. 2004. Human growth hormone and the temptations of biomedical enhancement. Sociol Health Dis 26:184-215.
6. Cottle M. 1999. Selling shyness: how doctors and drug companies created the "social phobia" epidemic. The New Republic, 2 August, www.tnr.com/archive/0899/080299/coverstoryo80299.html
7. DeFede J. 2004. The cop, the stripper and the Holy Toast. The Independent, 16 December, www.independent.co.uk.
8. Diamond J. 2004. Irritable male syndrome. New York: Rodal Books.
9. Doward J, McKie R. 2004. Revealed: secret plan to push "happy pills." The Observer (London), 7 November.
10. Elliott C. 2003. Better than well. American medicine meets the American dream. New York: Norton and Co.
11. Elliott S. 2004. FDA criticizes Viagra ads, prompting Pfizer to halt them. New York Times, 15 November.
12. FitzGerald GA. 2004. Coxibs and cardiovascular disease. New Engl J Med 351:1709-1711.
13. Flower R. 2004. Lifestyle drugs: pharmacology and the normal agenda. Trends Pharmacol Sci 25:182-185.
14. Fontanarosa PB, Rennie D, DeAngelis CD. 2004. Postmarketing surveillance: a lack of vigilance, lack of trust. JAMA 292: 2647-2650.
15. Friedman M. 1970. The social responsibility of business is to increase profits. New York Times Magazine, 13 September.
16. General Accounting Office (GAO). 2002. FDA oversight of direct-to-consumer advertising has limitations. http://www.gao.gov/new. items/do3177.pdf
17. Gilbert D, Walley T, New B. 2000. Lifestyle medicines. BMJ 321:1341-1344.
18. Goodman L. 2002. Celebrity pill pushers. Salon, July 11. www. salon.com
19. Graham DJ, Steffa JA, Shatin D, Andrade SE, Grenade LLa, Gurwitz, JH, Chan KA, Goodman MJ, Platt R. 2004. Incidence of hospitalized rhabdomyolosis in patients treated with lipid-lowering drugs. JAMA 292:2585-2590.
20. Hensley S, Liblin JS. 2004. Embattled Merck arms executives with golden parachutes. Wall Street Journal, B1 30 November.
21. Holmer AF. 2002. Direct-to-consumer advertising strengthens a health care system. New Engl J Med 346:526-528.
22. Horton R. 2004. Vioxx, the implosion of Meck, and aftershocks at the FDA. Lancet, 5 November, 364:1995-1996.
23. Judge TA, Cable TM. 2004. The effect of physical height on workplace success and income: preliminary test of a theoretical model. J Appl Psychol 89:428-441.
24. Kassirer JP. 2004. On the take. How medicine's complicity with big business can endanger your health. New York: Oxford University Press.
25. Kaufman R, Masters BA. 2004. FDA is flexing less muscle. Washington Post, 18 November.
26. Kay J. 2004. The sick need more than just healthy profits. Financial Times, 23 November.
27. Laumann EO, Paik MA, Rosen RC. 1999. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281: 537-544
28. Leacock S. 1924. The garden of folly. New York: Dodd Mead.
29. Lexechin J. 2001. Lifestyle drugs: issues for debate. Can Med Assoc J 164:1449-1451.
30. Mathews AW, Steinberg B. 2004. FDA proposes drug ads without the fine print. Wall Street Journal, 6 February.
31. Mitka M. 2003. Survey suggesting that prescription drug ads help public is met with skepticism. JAMA 287:827-828.
32. Moynihan R. 2003. The making of a disease: female sexual dysfunction. BMJ 326:45-48.
33. Moynihan R. 2004. Drug maker urges group to lobby FDA on testosterone for women. BMJ 329:1255.
34. Moynihan R, Heath I, Henry D. 2002. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 324: 886-891.
35. Murray A. 2004. Trade group's fight against drug review is self-defeating. Wall Street Journal, 30 November.
36. National Center for Health Statistics (NCHS). 2004. Health United States, www.cdc.gov/nchs/
37. National Institute for Health Care Management (NIHCM). Prescription drugs and mass media advertising 2000, 2001; November, www.nihcm.org
38. Pear R. 2002. Investigators find repeated deception in ads for drugs. New York Times, 4 December.
39. Pear R. 2004. Americans relying more on prescription drugs. New York Times, 3 December.
40. Pollack A. 2004a. Panel to review drug for low female sex drive. New York Times, 30 November.
41. Pollack A. 2004b. More data sought on drug for sex drive. New York Times, 3 December.
42. Psaty BM, Furberg CD, Ray WA, Weiss NS. 2004. Potential for conflict of interest in the evaluation of suspected adverse drug reactions. Use of cerivastatin and risk of rhabdomyolosis. JAMA 292:2622-2631.
43. Quinion M. 2002. Irritable male syndrome. Daily Mirror, March. www.worldwidewwords.org/turnsofphrase/tp-irrl.htm
44. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. 2002. Promotion of prescription drugs to consumers. New Engl J Med 346:498-505
45. Sandberg De, Bukowski WM, Fung CM, Noll RB. 2004. Height and social adjustment: are extremes a cause for concern and action? Pediatrics 114:744-750.
46. Shabsigh R, Anastesiadis AG. 2003. Erectile dysfunction. Ann Rev Med 54:153-168.
47. Spector IP, Carey MP. 1990. Incidence and prevalence of sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav 19:389-408.
48. Steffers M. 2003. Not just a headache, darling, www.abc.net.au/health/ features/headache/default.htm
49. Stock G. 2003. Stamping out short people. Wired Magazine, 11 November.
50. Tiefer L. 2000. Sexology and the pharmaceutical industry: the thread of co-optation. J Sex Res 37:273-283.
51. Topol EJ. 2004. Failing the public health: Rofecoxib, Merck and the FDA. New Engl J Med 351:1707-1709.
52. st century, or, pills, politics, potions and profits: where is public policy? Drug Dev Res 59: 269-291.
53. Vedantam S. 2004. Antidepressant use by U.S adults soars. New York Times, 3 December.
54. Waack KE, Ernst ME, Graber MA. 2004. Informational content of official pharmaceutical industry web sites about treatments for erectile dysfunction. Ann Pharmacother 38:2029-2034.